AJP - Gastrointestinal and Liver Physiology, Vol 259, Issue 3 468-G473, Copyright © 1990 by American Physiological Society

ARTICLES

Potent bombesin receptor antagonists distinguish receptor subtypes

T. von Schrenck, L. H. Wang, D. H. Coy, M. L. Villanueva, S. Mantey and R. T. Jensen
Digestive Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892.

To determine whether newly described bombesin (BN) receptor antagonists distinguish subtypes of BN receptors, we investigated their abilities to interact with BN receptors on esophageal muscle or pancreatic acinar tissue. For inhibition of binding of 125I-[Tyr4]BN to rat pancreatic tissue, the relative potencies were [D-Phe6]BN-(6-13)ethyl ester (5 nM) greater than Ac-gastrin-releasing peptide (GRP)-(20-26)ethyl ester (17 nM) greater than [D-Phe6,Cpa,14, psi 13-14]BN-(6-14) (40 nM) greater than [Leu14, psi 13-14]BN (0.43 microM) greater than [Tyr4,D-Phe12]BN = [D-Pro4, D-Trp7,9,10]substance P (SP)-4-11 (13 microM) greater than [Leu14, psi 9,10]BN (32 microM) greater than [D-Arg1,D-Trp7,9,Leu11]SP (70 microM). Each antagonist also inhibited binding of 125I-[Tyr4]BN or 125I-Bolton-Hunter-neuromedin B to rat esophageal tissue, and the potency of each antagonist for each tracer was similar. In comparison to rat pancreas, [D-Phe6]BN-(6-13)ethyl ester, Ac-GRP-(20-26)ethyl ester, [D-Phe6,Cpa14, psi 13-14]BN-(6-14), [Leu14, psi 13-14]BN, and [Leu14, psi 9,10]BN had a 10,000-, 2,940-, 1,425-, 122-, and 4-fold, respectively, weaker affinity for BN receptors. In contrast [Tyr4,D-Phe12]BN, [D-Pro4,D-Trp7,9,10]SP-4-11, and [D-Arg1,D-Trp7,9,Leu11]SP had a 4-, 4-, and 9-fold, respectively, higher affinity compared with pancreatic tissue. Comparison of the activity of each peptide at inhibiting the ability of equipotent concentrations of BN or neuromedin B to stimulate contraction of rat esophageal muscle demonstrated that each peptide had the same relative potencies as for inhibiting binding.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				J. R. Grider Gastrin-releasing peptide is a modulatory neurotransmitter of the descending phase of the peristaltic reflex Am J Physiol Gastrointest Liver Physiol, December 1, 2004; 287(6): G1109 - G1115. [Abstract] [Full Text] [PDF]

				A. Inui Transgenic Approach to the Study of Body Weight Regulation Pharmacol. Rev., March 1, 2000; 52(1): 35 - 62. [Abstract] [Full Text] [PDF]

				R. R. Ryan, H. C. Weber, W. Hou, E. Sainz, S. A. Mantey, J. F. Battey, D. H. Coy, and R. T. Jensen Ability of Various Bombesin Receptor Agonists and Antagonists to Alter Intracellular Signaling of the Human Orphan Receptor BRS-3 J. Biol. Chem., May 29, 1998; 273(22): 13613 - 13624. [Abstract] [Full Text] [PDF]

				L. L. Hampton, E. E. Ladenheim, M. Akeson, J. M. Way, H. C. Weber, V. E. Sutliff, R. T. Jensen, L. J. Wine, H. Arnheiter, and J. F. Battey Loss of bombesin-induced feeding suppression in gastrin-releasing peptide receptor-deficient mice PNAS, March 17, 1998; 95(6): 3188 - 3192. [Abstract] [Full Text] [PDF]

				S. A. Mantey, H. C. Weber, E. Sainz, M. Akeson, R. R. Ryan, T. K. Pradhan, R. P. Searles, E. R. Spindel, J. F. Battey, D. H. Coy, et al. Discovery of a High Affinity Radioligand for the Human Orphan Receptor, Bombesin Receptor Subtype 3, Which Demonstrates That It Has a Unique Pharmacology Compared with Other Mammalian Bombesin Receptors J. Biol. Chem., October 10, 1997; 272(41): 26062 - 26071. [Abstract] [Full Text] [PDF]